Edition:
United Kingdom

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

148.50USD
11 Dec 2017
Change (% chg)

$0.50 (+0.34%)
Prev Close
$148.00
Open
$148.64
Day's High
$149.76
Day's Low
$147.55
Volume
239,796
Avg. Vol
371,003
52-wk High
$192.15
52-wk Low
$137.20

Latest Key Developments (Source: Significant Developments)

Shire Plc Appoints ‍John Miller As Interim CFO
Friday, 8 Dec 2017 

Dec 8 (Reuters) - Shire PLC ::SHIRE PLC SAYS ‍JOHN MILLER TO SERVE AS INTERIM CFO WITH EFFECT FROM JAN 1, 2018 UNTIL THOMAS DITTRICH COMMENCES HIS EMPLOYMENT WITH CO - SEC FILING​.SAYS ‍MILLER ENTERED NEW LETTER AGREEMENT WITH CO PURSUANT TO WHICH HIS ANNUAL BASE SALARY TO INCREASE TO $765,000​ WHILE SERVING AS INTERIM CFO.  Full Article

Shire And Rani Therapeutics enter into collaboration to evaluate use of the Rani Pill technology
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Shire Plc ::SHIRE AND RANI THERAPEUTICS ENTER INTO COLLABORATION TO EVALUATE USE OF THE RANI PILL(TM) TECHNOLOGY FOR THE ORAL DELIVERY OF FACTOR THERAPY.- AS PART OF COLLABORATION, SHIRE HAS ALSO MADE AN EQUITY INVESTMENT INTO RANI THERAPEUTICS.SAYS SPECIFIC TERMS OF THIS DEAL WERE NOT DISCLOSED.  Full Article

Shire names Thomas Dittrich as CFO
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Shire Plc :Shire Plc <<>> says Thomas Dittrich will join company as chief financial officer​.Shire Plc <<>> says Thomas Dittrich will assume his role as CFO in early 2018 following a transition period from his current employer​.  Full Article

Omega Advisors dissolves share stake in Carrizo Oil & Gas, ups in Shire PLC
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Omega Advisors Inc::Omega Advisors Inc dissolves share stake in Carrizo Oil & Gas Inc - SEC Filing‍​.Omega Advisors Inc raises share stake in Shire PLC by about 31 percent to 653,977 sponsored ADRs.Omega Advisors Inc - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.  Full Article

Shire says CHMP recommends EU marketing authorization for ADYNOVI [Antihemophilic Factor (Recombinant), PEGylated]
Monday, 13 Nov 2017 

Nov 13 (Reuters) - SHIRE PLC ::CHMP RECOMMENDS EU MARKETING AUTHORIZATION FOR ADYNOVI [antihemophilic factor (recombinant), pegylated] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​.  Full Article

Third Point takes share stake in Macerich, dissolves share stake in Humana
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - ‍THIRD POINT LLC​:Third Point LLC dissolves Class A share stake in Charter Communications Inc <<>> - SEC filing.Third Point LLC dissolves share stake in Hewlett Packard Enterprise.Third Point LLC dissolves share stake in Humana Inc.Third Point LLC raises share stake in Alibaba Group Holding Ltd by about 47 percent to 6.6 million Sponsored ADS.Third Point LLC dissolves share stake in General Dynamics Corp.Third Point LLC takes share stake of 1.2 million Sponsored ADR in Shire Plc.Third Point LLC cuts share stake in T-Mobile US Inc by about 27 percent to 3.9 million shares.Third Point LLC cuts share stake in Time Warner Inc by about 27 percent to 2.8 million shares.Third Point LLC takes share stake of 1.7 million shares in Macerich Co.Third Point LLC takes share stake of 2.8 million shares in Marathon Petroleum Corp.Third Point LLC reports share stake of 750,000 shares in Altaba Inc.‍Third Point LLC - Change in holdings are as of Sept 30, 2017 and compared with the previous quarter ended as of June 30, 2017.  Full Article

Shire receives European approval for label extension of firazyr for symptomatic treatment
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - SHIRE PLC ::SHIRE RECEIVES EUROPEAN APPROVAL FOR LABEL EXTENSION OF FIRAZYR (ICATIBANT INJECTION) FOR THE SYMPTOMATIC TREATMENT OF ACUTE HAE ATTACKS IN PAEDIATRIC PATIENTS.FIRAZYR WILL BE AVAILABLE FOR USE IN PAEDIATRIC PATIENTS IN EUROPE BEGINNING IN Q4​.  Full Article

Shire receives orphan drug designation for gene therapy candidate for treatment of Hemophilia A
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - Shire Plc :SHIRE RECEIVES ORPHAN DRUG DESIGNATION FOR GENE THERAPY CANDIDATE SHP654 (BAX 888) FOR THE TREATMENT OF HEMOPHILIA A.‍SHP654 INVESTIGATIONAL NEW DRUG (IND) APPLICATION ACCEPTED BY FDA​.RECEIVES ORPHAN DRUG DESIGNATION FOR GENE THERAPY CANDIDATE SHP654 (BAX 888) FOR TREATMENT OF HEMOPHILIA A​.‍REGULATORY AGENCY ALSO GRANTED SHIRE INVESTIGATIONAL NEW DRUG (IND) STATUS FOR SHP654​.ALSO RECEIVED FDA CLEARANCE FOR IND APPLICATION IT SUBMITTED EARLIER THIS YEAR TO INITIATE A GLOBAL MULTI-CENTER STUDY​.‍COMPANY ANTICIPATES THAT SHP654 PHASE 1/2 STUDY WILL BEGIN BY END OF 2017​.  Full Article

Shire says EU regulator backs new formulation of blood cancer treatment
Friday, 13 Oct 2017 

Oct 13 (Reuters) - SHIRE PLC ::NEW FORMULATION OF ONCASPAR® (PEGASPARGASE) RECEIVES POSITIVE CHMP OPINION IN EUROPE FOR PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA.EMA'S CHMP ADOPTED A POSITIVE OPINION RECOMMENDING MARKETING AUTHORIZATION FOR LYOPHILIZED ONCASPAR​.  Full Article

Shire plc says U.S. FDA approves Mydayis
Tuesday, 20 Jun 2017 

June 20 (Reuters) - Shire Plc :U.S. FDA approves MydayisTM (mixed salts of a single-entity amphetamine product) - a new once-daily option for ADHD symptom control in patients 13 years and older.Expects to make Mydayis commercially available in United States in Q3 of 2017.Shire plc says expects to make Mydayis commercially available in United States in Q3 of 2017.  Full Article

BRIEF-Shire Plc Appoints ‍John Miller As Interim CFO

* SHIRE PLC SAYS ‍JOHN MILLER TO SERVE AS INTERIM CFO WITH EFFECT FROM JAN 1, 2018 UNTIL THOMAS DITTRICH COMMENCES HIS EMPLOYMENT WITH CO - SEC FILING​